Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY900020 · 1 trial · 1 indication
PK: AUC of LY900020
PK: Cmax of LY900020
| Arm | Type | Description |
|---|---|---|
| LY900020 Formulation 1 | EXPERIMENTAL | LY900020 Formulation 1 administered orally |
| LY900020 Formulation 2 | EXPERIMENTAL | LY900020 Formulation 2 administered orally |
| LY900020 Formulation 3 | EXPERIMENTAL | LY900020 Formulation 3 administered orally |
| Reference Drugs | ACTIVE_COMPARATOR | Metformin XR, atorvastatin, and valsartan administered orally |
| Name | Type | Description |
|---|---|---|
| LY900020 | DRUG | Administered orally |
| Metformin XR | DRUG | Administered orally |
| Atorvastatin | DRUG | Administered orally |
| Valsartan | DRUG | Administered orally |
Inclusion Criteria: * Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion) * Have a body mass index (BMI) of 18.5 to 35 kilogram per square meter (kg/m²), inclusive, at screening * Have normal blood pressure, pulse rate, electrocardiogr...
LY900020 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy Chinese participants. The specific therapeutic indication for LY900020 has not been disclosed.
LY900020 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program for this investigational small molecule.
LY900020 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not been approved by the FDA.
LY900020 has been evaluated in one completed Phase 1 trial, NCT04047940, titled A Study of LY900020 in Healthy Chinese Participants. The trial enrolled 32 healthy volunteers in Singapore, was randomized and active-controlled, and included participants aged 21 years and older.
No. LY900020 is an investigational drug in Phase 1 clinical development and has not been approved by the FDA. It has completed one Phase 1 trial in healthy Chinese participants, and no active trials are currently listed.